Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Immunol. 2018 May 11;201(1):278–295. doi: 10.4049/jimmunol.1701069

Figure 2.

Figure 2

Impairment of B cell subsets in the BM and spleens of tumor-bearing mice. Percentages of Pro- and mature B cells were reduced whereas absolute numbers of Pro-, Pre-, immature and mature B cells decreased in bone marrow of tumor-bearing mice after intravenous challenge with LLC tumor cells. (A) The percentages of total B220+, Pro-, Pre-, immature, and mature B cells were determined by FACS analysis of cells harvested from the BM of naïve and tumor-bearing mice on day 16 post-LLC intravenous challenge (n = 8 mice/group). (B) Absolute numbers of total B220+, Pro-, Pre-, immature, and mature B cells in the BM were calculated. Percentages and absolute numbers of follicular B cells were reduced, while immature B cells were increased in the spleens of tumor-bearing mice on day 16 post-LLC intravenous challenge with LLC tumor cells (n = 8 mice/group). (C) The percentages of total B, immature B, marginal zone B, and follicular B cells were determined by FACS analysis of cells harvested from the spleens of naïve and tumor-bearing mice on day 16 post-LLC intravenous challenge (n = 8 mice/group). (D) Absolute numbers of total B, immature B, marginal zone B, and follicular B cells in the spleens are presented (n = 8 mice/group). **, P < 0.01; ***, P < 0.001.